These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 30243754)

  • 21. [Abiraterone in castration resistant prostate cancer.].
    Juárez Soto A; Caballero Cobos R; Campanario Pérez R; Saiz Marenco R; Herrera Torres M; Gamaza Martínez R; Amores Bermúdez J
    Arch Esp Urol; 2018 Sep; 71(8):651-663. PubMed ID: 30319125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
    Loblaw DA; Walker-Dilks C; Winquist E; Hotte SJ;
    Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):406-30. PubMed ID: 23587782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.
    Todenhöfer T; Azad A; Stewart C; Gao J; Eigl BJ; Gleave ME; Joshua AM; Black PC; Chi KN
    J Urol; 2017 Jan; 197(1):135-142. PubMed ID: 27436429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Clarke N; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Goessl C; Burgents J; Kozarski R; Hodgson D; Learoyd M; Saad F
    Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A single-center experience with abiraterone as treatment for metastatic castration-resistant prostate cancer.
    Thortzen A; Thim S; Røder MA; Brasso K
    Urol Oncol; 2016 Jul; 34(7):291.e1-7. PubMed ID: 26971191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer.
    Fenioux C; Louvet C; Charton E; Rozet F; Ropert S; Prapotnich D; Barret E; Sanchez-Salas R; Mombet A; Cathala N; Joulia ML; Molitor JL; Henriques J; Bonnetain F; Cathelineau X; Bennamoun M
    BJU Int; 2019 Feb; 123(2):300-306. PubMed ID: 30099821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spatial vs. non-spatial eco-evolutionary dynamics in a tumor growth model.
    You L; Brown JS; Thuijsman F; Cunningham JJ; Gatenby RA; Zhang J; Staňková K
    J Theor Biol; 2017 Dec; 435():78-97. PubMed ID: 28870617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A case of metastatic castration-resistant prostate cancer by abiraterone treatment].
    Li L; Long Z; He L
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2015 Jun; 40(6):688-92. PubMed ID: 26164521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimization of therapies for men with advanced prostate cancer: a review of recent developments with a look toward the future.
    Gourdin T
    Curr Opin Oncol; 2019 May; 31(3):188-193. PubMed ID: 30925537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
    Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM
    Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current management of advanced and castration resistant prostate cancer.
    Gomella LG; Petrylak DP; Shayegan B
    Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry.
    Akaza H; Procopio G; Pripatnanont C; Facchini G; Fava S; Wheatley D; Leung KC; Butt M; Silva A; Castillo L; Karavasilis V; Ӧzatılgan A; Hitier S; Ecstein-Fraisse EB; Ӧzgüroḡlu M
    J Glob Oncol; 2018 Sep; 4():1-12. PubMed ID: 30260754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness analysis of abiraterone and sipuleucel-T in asymptomatic metastatic castration-resistant prostate cancer.
    Gong CL; Hay JW
    J Natl Compr Canc Netw; 2014 Oct; 12(10):1417-25. PubMed ID: 25313181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimizing Cancer Treatment Using Game Theory: A Review.
    Stanková K; Brown JS; Dalton WS; Gatenby RA
    JAMA Oncol; 2019 Jan; 5(1):96-103. PubMed ID: 30098166
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Castration-resistance prostate cancer: what is in the pipeline?
    DE Nunzio C; Presicce F; Giacinti S; Bassanelli M; Tubaro A
    Minerva Urol Nefrol; 2018 Feb; 70(1):22-41. PubMed ID: 28707844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Health-related quality of life in men with metastatic castration-resistant prostate cancer.
    Gee A; Challapalli A; Bahl A
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):941-9. PubMed ID: 26512743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment.
    Aggarwal R; Harris A; Formaker C; Small EJ; Molina A; Griffin TW; Ryan CJ
    Clin Genitourin Cancer; 2014 Oct; 12(5):e167-72. PubMed ID: 24787968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW
    Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8
    Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM
    Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer.
    Burgio SL; Conteduca V; Rudnas B; Carrozza F; Campadelli E; Bianchi E; Fabbri P; Montanari M; Carretta E; Menna C; De Giorgi U
    Clin Genitourin Cancer; 2015 Feb; 13(1):39-43. PubMed ID: 24999168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.